Drug Delivery by Exosome
Investing in the Future of
Exosome Therapies
NurExone is addressing multi-billion dollar global markets with the first two central nervous system (CNS) indications focused on acute spinal cord injury and acute glaucoma. Each of these markets represent an area of tremendous unmet need, representing a combined patient population of over 1.5M globally
December 10th, 2025 | 10:00 AM ET
Where Nature Ends, NurExone Begins
Exosome based therapies
Potential and Benefits
NurExone chose to base its ultimate drug delivery platform on exosomes-nanosized extracellular vesicles-due to their natural ability to reach inflamed or damaged tissue. By loading exosomes with therapeutic compounds, nanodrugs are created having natural regenerative properties and therapeutic impact.
Minimal Invasive
Off the shelf targeted medicine
Cell-free
Crosses the
Blood Brain Barrier
Regenerate, Rewire, Recover
First product from the ExoTherapy platform
ExoPTEN for acute spinal cord injury
MRI images of laboratory rats
NurExone ExoTherapy Platform
for Minimal Invasive Nanodrugs
Exosome
The company’s dedicated in-house bioreactor produces potent exosomes with high quality and large scale using proprietary 2D and 3D production processes.
Active Pharmaceutical Ingredient (API)
The company’s team of biologists and PhDs sysnthesizes compounds with therapeutic properties and active pharmaceutical ingredients
Nanodrug
Nanodrugs are created by loading the therapeutic compound onto exosomes (short peptides, molecules). Known APIs can be repurposed and loaded onto the exosomes under a proprietary loading process.
Where nature ends, NurExone begins
As we unharness the power of exosomes to push the edge of medicine and biology, our ExoTherapy platform technology for producing and loading quality exosomes will incorporate new, exciting technologies and IP that may be licensed and spun off for other applications, and indications, driving early revenues and creating value for shareholders.
